Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-19T13:07:44.474Z Has data issue: false hasContentIssue false

Monoamine Oxidase Inhibitor Antidepressants

from Part II - Medication Reference Tables

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 328 - 344
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Shulman, K. I., Herrmann, N., Walker, S. E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs, 27, 789–797.CrossRefGoogle ScholarPubMed
Kennedy, S. H. (1997). Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors. J Psychiatry Neurosci, 22, 127–131.Google ScholarPubMed
Zisook, S. (1984). Side effects of isocarboxazid. J Clin Psychiatry, 45, 53–58.Google ScholarPubMed
Larsen, J. K., Bendsen, B. B., Bech, P. (2011). Vitamin B6 treatment of oedema induced by mirtazapine and isocarboxazid. Acta Psychiatr Scand, 124, 76–77; discussion 77.CrossRefGoogle ScholarPubMed
Koechlin, B. A., Schwartz, M. A., Oberhaensli, W. E. (1962). Metabolism of C-14-iproniazid and C-14-isocarboxazid in man. J Pharmacol Exp Ther, 138, 11–20.Google Scholar
Davidson, J. R., Giller, E. L., Zisook, S., et al. (1988). An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry, 45, 120–127.CrossRefGoogle ScholarPubMed
Thase, M. E., Trivedi, M. H., Rush, A. J. (1995). MAOIs in the contemporary treatment of depression. Neuropsychopharmacology, 12, 185–219.Google Scholar

References

Bonnet, U. (2003). Moclobemide: therapeutic use and clinical studies. CNS Drug Rev, 9, 97–140.CrossRefGoogle ScholarPubMed
Kennedy, S. H. (1997). Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors. J Psychiatry Neurosci, 22, 127–131.Google ScholarPubMed
Shulman, K. I., Herrmann, N., Walker, S. E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs, 27, 789–797.Google Scholar
Macaluso, M., Preskorn, S. H. (2011). CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism? J Clin Psychopharmacol, 31, 143–145.CrossRefGoogle ScholarPubMed
Schoerlin, M. P., Horber, F. F., Frey, F. J., et al. (1990). Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. J Clin Pharmacol, 30, 272–284.CrossRefGoogle ScholarPubMed
Stoeckel, K., Pfefen, J. P., Mayersohn, M., et al. (1990). Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand Suppl, 360, 94–97.CrossRefGoogle ScholarPubMed
Mayersohn, M., Guentert, T. W. (1995). Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet, 29, 292–332.Google Scholar
Amrein, R., Stabl, M., Henauer, S., et al. (1997). Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview. Can J Psychiatry, 42, 1043–1050.CrossRefGoogle ScholarPubMed
Papakostas, G. I., Thase, M. E., Fava, M., et al. (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry, 62, 1217–1227.CrossRefGoogle Scholar
Kriston, L., von Wolff, A., Westphal, A., et al. (2014). Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety, 31, 621–630.CrossRefGoogle ScholarPubMed
Bandelow, B., Reitt, M., Röver, C., et al. (2015). Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol, 30, 183–192.CrossRefGoogle ScholarPubMed

References

Shulman, K. I., Herrmann, N., Walker, S. E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs, 27, 789–797.CrossRefGoogle ScholarPubMed
Kennedy, S. H. (1997). Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors. J Psychiatry Neurosci, 22, 127–131.Google ScholarPubMed
Tyrer, P., Gardner, M., Lambourn, J., et al. (1980). Clinical and pharmacokinetic factors affecting response to phenelzine. Br J Psychiatry, 136, 359–365.CrossRefGoogle ScholarPubMed
Malcolm, D. E., Yu, P. H., Bowen, R. C., et al. (1994). Phenelzine reduces plasma vitamin B6. J Psychiatry Neurosci, 19, 332–334.Google ScholarPubMed
Birkenhager, T. K., van den Broek, W. W., Mulder, P. G., et al. (2004). Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry, 65, 1505–1510.CrossRefGoogle ScholarPubMed
Robinson, D. S., Cooper, T. B., Jindal, S. P., et al. (1985). Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans. J Clin Psychopharmacol, 5, 333–337.CrossRefGoogle ScholarPubMed
Chiuccariello, L., Cooke, R. G., Miler, L., et al. (2015). Monoamine oxidase-A occupancy by moclobemide and phenelzine: implications for the development of monoamine oxidase inhibitors. Int J Neuropsychopharmacol, 19(1), pyv078.Google ScholarPubMed
Thase, M. E., Trivedi, M. H., Rush, A. J. (1995). MAOIs in the contemporary treatment of depression. Neuropsychopharmacol, 12, 185–219.CrossRefGoogle ScholarPubMed

References

Shulman, K. I., Herrmann, N., Walker, S. E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs, 27, 789–797.CrossRefGoogle ScholarPubMed
Lee, K. C., Chen, J. J. (2007). Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat, 3, 527–537.Google ScholarPubMed
Clarke, A., Brewer, F., Johnson, E. S., et al. (2003). A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm (Vienna), 110, 1241–1255.CrossRefGoogle ScholarPubMed
Goodnick, P. J. (2007). Seligiline transdermal system in depression. Expert Opin Pharmacother, 8, 59–64.Google Scholar
Patkar, A. A., Pae, C. U., Masand, P. S. (2006). Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr, 11, 363–375.CrossRefGoogle ScholarPubMed
Blob, L. F., Sharoky, M., Campbell, B. J., et al. (2007). Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. CNS Spectr, 12, 25–34.Google Scholar

References

Shulman, K. I., Herrmann, N., Walker, S. E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs, 27, 789–797.CrossRefGoogle ScholarPubMed
Kennedy, S. H. (1997). Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors. J Psychiatry Neurosci, 22, 127–131.Google ScholarPubMed
Mallinger, A. G., Himmelhoch, J. M., Thase, M. E., et al. (1990). Plasma tranylcypromine: relationship to pharmacokinetic variables and clinical antidepressant actions. J Clin Psychopharmacol, 10, 176–183.CrossRefGoogle ScholarPubMed
Ulrich, S., Ricken, R., Buspavanich, P., et al. (2020). Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: a systematic review and comprehensive meta-analysis. J Clin Psychopharmacol, 40, 63–74.Google Scholar
Morgan, M. H., Read, A. E. (1972). Antidepressants and liver disease. Gut, 13, 697–701.CrossRefGoogle ScholarPubMed
Mallinger, A. G., Edwards, D. J., Himmelhoch, J. M., et al. (1986). Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clin Pharmacol Ther, 40, 444–450.CrossRefGoogle ScholarPubMed
Ulrich, S., Ricken, R., Adli, M. (2017). Tranylcypromine in mind (part I): review of pharmacology. Eur Neuropsychopharmacol, 27, 697–713.CrossRefGoogle ScholarPubMed
Thase, M. E., Trivedi, M. H., Rush, A. J. (1995). MAOIs in the contemporary treatment of depression. Neuropsychopharmacol, 12, 185–219.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×